Low expression of miR‑199 in hepatocellular carcinoma contributes to tumor cell hyper‑proliferation by negatively suppressing XBP1

Lou,Zheng; Gong,Yong‑Qiang; Zhou,Xing; Hu,Guo‑Huang

doi:10.3892/ol.2018.9476

Low expression of miR‑199 in hepatocellular carcinoma contributes to tumor cell hyper‑proliferation by negatively suppressing XBP1

Authors:
- Zheng Lou
- Yong‑Qiang Gong
- Xing Zhou
- Guo‑Huang Hu
View Affiliations

Affiliations: Key Laboratory Breeding Base of Hunan Oriented Fundamental and Applied Research of Innovative Pharmaceutics, Changsha Medical University, Changsha, Hunan 410219, P.R. China, Department of General Surgery, Institute of Digestive Surgery of Changsha, Affiliated Changsha Hospital of Hunan Normal University, Changsha, Hunan 410006, P.R. China
Published online on: September 21, 2018 https://doi.org/10.3892/ol.2018.9476
Pages: 6531-6539
Copyright: © Lou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinoma (HCC) is the third leading cause of cancer‑related mortality worldwide, and microRNAs (miRs) are considered to serve important functions in the pathogenesis of HCC by regulating the expression of specific target genes. The present study was conducted to investigate the role of miR‑199 and its putative target X‑box binding protein 1 (XBP1) in HCC, as well as of the downstream gene cyclin D. The expression levels of miR‑199, XBP1 and cyclin D were detected in clinical HCC specimens. The effect of miR‑199 on the regulation of HCC cell proliferation and its underlying mechanism were examined in Hep3B2.1‑7 cells, through expression assays and measurement of cell proliferation (via Cell Counting Kit‑8, and 5‑ethynyl‑2'‑deoxyuridine and DAPI double‑staining assays) coupled with gain‑ and lose‑ of function experiments. The expression of XBP1 and cyclin D was significantly increased in HCC tissues when compared with adjacent non‑HCC tissues, while the expression of miR‑199 was decreased. Exogenous miR‑199 significantly suppressed the expression of XBP1 and cyclin D in Hep3B2.1‑7 cells. However, the expression of XBP1 and cyclin D significantly increased on treatment with miR‑199 inhibitor. Consistently, Hep3B2.1‑7 cells co‑transfected with a wild type reporter plasmid [XBP1‑3'untranslated region (UTR)‑WT] and exogenous miR‑199 exhibited lower relative luciferase enzyme activity than cells co‑transfected with negative control miRNA and XBP1‑3'UTR‑WT, while cells co‑transfected with mutated plasmid (XBP1‑3'UTR‑MU) and miR‑199 exhibited no change. It was further observed that knockdown of XBP1 by small interfering RNA significantly decreased the expression of cyclin D in Hep3B2.1‑7 cells. Additionally, exogenous miR‑199 decreased the proliferation of Hep3B2.1‑7 cells, which was contrary to the effect of miR‑199 inhibitor. In conclusion, it was demonstrated that miR‑199 negatively regulated the expression of XBP1 by directly binding to its 3'UTR and that XBP1 impacted cyclin D expression, which was associated with the cell cycle regulation in Hep3B2.1‑7 cells. These findings suggested that a miR‑199/XBP1/cyclin D axis may serve an important role in the pathogenesis of HCC.

View Figures

View References

1	Sanyal AJ, Yoon SK and Lencioni R: The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist. 15 Suppl 4:S14–S22. 2010. View Article : Google Scholar
2	Pievsky D and Pyrsopoulos N: Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: The evidence to date. J Hepatocell Carcinoma. 3:69–76. 2016. View Article : Google Scholar : PubMed/NCBI
3	Enguita-Germán M and Fortes P: Targeting the insulin-like growth factor pathway in hepatocellular carcinoma. World J Hepatol. 6:716–737. 2014. View Article : Google Scholar : PubMed/NCBI
4	Feitelson MA, Arzumanyan A, Kulathinal RJ, Blain SW, Holcombe RF, Mahajna J, Marino M, Martinez-Chantar ML, Nawroth R, Sanchez-Garcia I, Sharma D, et al: Sustained proliferation in cancer: Mechanisms and novel therapeutic targets. Semin Cancer Biol. 35:S25–S54. 2015. View Article : Google Scholar : PubMed/NCBI
5	Derenzini M, Trerè D, Pession A, Govoni M, Sirri V and Chieco P: Nucleolar size indicates the rapidity of cell proliferation in cancer tissues. J Pathol. 191:181–186. 2000. View Article : Google Scholar : PubMed/NCBI
6	López-Sáez JF, de la Torre C, Pincheira J and Giménez-Martín G: Cell proliferation and cancer. Histol Histopathol. 13:1197–1214. 1998.PubMed/NCBI
7	Glimcher LH: XBP1: The last two decades. Ann Rheum Dis. 69 Suppl 1:i67–i71. 2010. View Article : Google Scholar : PubMed/NCBI
8	Marumoto Y, Terai S, Urata Y, Matsumoto T, Mizunaga Y, Yamamoto N, Jin H, Fujisawa K, Murata T, Shinoda K, et al: Continuous high expression of XBP1 and GRP78 is important for the survival of bone marrow cells in CCl4-treated cirrhotic liver. Biochem Biophys Res Commun. 367:546–552. 2008. View Article : Google Scholar : PubMed/NCBI
9	Chen X, Iliopoulos D, Zhang Q, Tang Q, Greenblatt MB, Hatziapostolou M, Lim E, Tam WL, Ni M, Chen Y, et al: XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway. Nature. 508:103–107. 2014. View Article : Google Scholar : PubMed/NCBI
10	Ming J, Ruan S, Wang M, Ye D, Fan N, Meng Q, Tian B and Huang T: A novel chemical, STF-083010, reverses tamoxifen-related drug resistance in breast cancer by inhibiting IRE1/XBP1. Oncotarget. 6:40692–40703. 2015. View Article : Google Scholar : PubMed/NCBI
11	Liu Y, Hou X, Liu M, Yang Z, Bi Y, Zou H, Wu J, Che H, Li C, Wang X, et al: XBP1 silencing decreases glioma cell viability and glycolysis possibly by inhibiting HK2 expression. J Neurooncol. 126:455–462. 2016. View Article : Google Scholar : PubMed/NCBI
12	Chae U, Park SJ, Kim B, Wei S, Min JS, Lee JH, Park SH, Lee AH, Lu KP, Lee DS and Min SH: Critical role of XBP1 in cancer signalling is regulated by PIN1. Biochem J. 473:2603–2610. 2016. View Article : Google Scholar : PubMed/NCBI
13	Sun H, Lin DC, Guo X, Masouleh Kharabi B, Gery S, Cao Q, Alkan S, Ikezoe T, Akiba C, Paquette R, et al: Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia. Oncotarget. 7:18736–18749. 2016.PubMed/NCBI
14	Diehl JA, Fuchs SY and Koumenis C: The cell biology of the unfolded protein response. Gastroenterology. 14138(41–41): e1–2. 2011. View Article : Google Scholar : PubMed/NCBI
15	Zhang D and Richardson DR: Endoplasmic reticulum protein 29 (ERp29): An emerging role in cancer. Int J Biochem Cell Biol. 43:33–36. 2011. View Article : Google Scholar : PubMed/NCBI
16	Greene CM, Varley RB and Lawless MW: MicroRNAs and liver cancer associated with iron overload: Therapeutic targets unravelled. World J Gastroenterol. 19:5212–5226. 2013. View Article : Google Scholar : PubMed/NCBI
17	Xiao F, Zhang W, Chen L, Chen F, Xie H, Xing C, Yu X, Ding S, Chen K, Guo H, et al: MicroRNA-503 inhibits the G1/S transition by downregulating cyclin D3 and E2F3 in hepatocellular carcinoma. J Transl Med. 11:1952013. View Article : Google Scholar : PubMed/NCBI
18	Wang W, Zhao LJ, Tan YX, Ren H and Qi ZT: MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma. Carcinogenesis. 33:1113–1120. 2012. View Article : Google Scholar : PubMed/NCBI
19	Duan Q, Wang X, Gong W, Ni L, Chen C, He X, Chen F, Yang L, Wang P and Wang DW: ER stress negatively modulates the expression of the miR-199a/214 cluster to regulates tumor survival and progression in human hepatocellular cancer. PLoS One. 7:e315182012. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Yu MC, Yuan JM and Lu SC: Alcohol, cofactors and the genetics of hepatocellular carcinoma. J Gastroenterol Hepatol. 23 suppl 1:S92–S97. 2008. View Article : Google Scholar : PubMed/NCBI
22	El-Serag HB and Rudolph KL: Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
23	Poon D, Anderson BO, Chen LT, Tanaka K, Lau WY, Van Cutsem E, Singh H, Chow WC, Ooi LL, Chow P, et al: Management of hepatocellular carcinoma in Asia: Consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 10:1111–1118. 2009. View Article : Google Scholar : PubMed/NCBI
24	Monga SP: Role of Wnt/β-catenin signaling in liver metabolism and cancer. Int J Biochem Cell Biol. 43:1021–1029. 2011. View Article : Google Scholar : PubMed/NCBI
25	Bisteau X, Caldez MJ and Kaldis P: The complex relationship between liver cancer and the cell cycle: A story of multiple regulations. Cancers (Basel). 6:79–111. 2014. View Article : Google Scholar : PubMed/NCBI
26	Breuhahn K, Longerich T and Schirmacher P: Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene. 25:3787–3800. 2006. View Article : Google Scholar : PubMed/NCBI
27	Hasegawa D, Calvo V, Avivar-Valderas A, Lade A, Chou HI, Lee YA, Farias EF, Aguirre-Ghiso JA and Friedman SL: Epithelial Xbp1 is required for cellular proliferation and differentiation during mammary glanddevelopment. Mol Cell Biol. 35:1543–1556. 2015. View Article : Google Scholar : PubMed/NCBI
28	Xia T, Tong S, Fan K, Zhai W, Fang B, Wang SH and Wang JJ: XBP1 induces MMP-9 expression to promote proliferation and invasion in human esophagealsquamous cell carcinoma. Am J Cancer Res. 6:2031–2040. 2016.PubMed/NCBI
29	Yang J, Cheng D, Zhou S, Zhu B, Hu T and Yang Q: Overexpression of X-Box binding protein 1 (XBP1) correlates to poor prognosis and up-regulation of PI3K/mTOR in human osteosarcoma. Int J Mol Sci. 16:28635–28646. 2015. View Article : Google Scholar : PubMed/NCBI
30	Li CW, Chang PY and Chen BS: Investigating the mechanism of hepatocellular carcinoma progression by constructing geneticand epigenetic networks using NGS data identification and big database mining method. Oncotarget. 7:79453–79473. 2016.PubMed/NCBI
31	El-Abd NE, Fawzy NA, El-Sheikh SM and Soliman ME: Circulating miRNA-122, miRNA-199a, and miRNA-16 as biomarkers for early detection of hepatocellular carcinoma in egyptian patients with chronic hepatitis c virus infection. Mol Diagn Ther. 19:213–220. 2015. View Article : Google Scholar : PubMed/NCBI